Search Results
Your search for ,maY matches 16907 pages
Showing 6001 - 6050Combination of Nivolumab and Ipilimumab for Unresectable Malignant Pleural Mesothelioma
On October 2, 2020, the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) was approved for first-line treatment of adult patients with unresectable malignant pleural mesothelioma.1-3 Supporting Efficacy Data Approval was based on findings in the open-label phase III CheckMate 743 trial...
Predicting Cardiovascular Disease Risk Via Routine CT Scans in Women With Breast Cancer
Coronary artery calcification scores based on routine computed tomography (CT) scans used for planning radiotherapy therapy may be able to predict which women with breast cancer have a high probability of developing cardiovascular disease. The promise of this research is that once high-risk...
Using Meaning-Centered Interventions to Address Suffering on the Cancer Journey
A large body of research has shed light on how the cancer experience and related losses often leave patients and their families struggling to find a sense of meaning in their lives.1-7 The COVID-19 pandemic has amplified these difficulties, as meaningful activities and experiences have been...
PALOMA-3 Exploratory Analysis: Who Benefits Most From Palbociclib?
The phase III PALOMA-3 trial significantly reduced the risk of disease progression by 50% in patients with hormone receptor–positive/HER2-negative advanced breast cancer, but the improvement in overall survival did not reach statistical significance.1 An exploratory subgroup analysis has now shown...
Pancreatic Adenocarcinoma: Leveraging Molecular Data to Drive Clinical Advances
With the worst 5-year overall survival of all cancers and the second-leading cause of cancer death, pancreatic adenocarcinoma remains a dismal prognosis for the vast majority of patients. However, more accurate tumor staging and better understanding of distinct molecular subgroups have started to...
Committed to Excellence: Oncology Drug Development Marches on Amid a Pandemic
Instituted as part of the 21st Century Cures Act, the Oncology Center of Excellence (OCE) fosters a unified interaction between three U.S. Food and Drug Administration (FDA) centers: Center for Biologics Evaluation and Research, Center for Drug Evaluation and Research, and Center for Devices and...
Liquid Biopsy: Mounting Evidence Shows Clinical Utility in Tumor Monitoring
A “blood-first” approach could soon shift the diagnostic paradigm in advanced lung cancer, replacing tissue biopsy with minimally invasive assays. According to Natasha B. Leighl, MD, MMSc, FRCPC, FASCO, there is rapidly mounting evidence that liquid biopsy serves a prognostic function in advanced...
Reducing Emergency Department Visits: Better Patient Outreach May Improve Care, Treatment Costs
Identifying patients at risk for adverse outcomes and intervening with intensive clinical services may improve cancer care while saving billions of dollars in avoidable emergency department (ED) visits. And, in fact, cancer centers may already have all the information they need to do so, according...
Medical Financial Hardship: Pervasive and Possibly Linked to Mortality Among Patients With Cancer
Reducing the financial impact of cancer diagnosis and treatment may save not only bank accounts but lives as well, according to recent data. Two separate survey studies presented during the 2020 ASCO Quality Care Symposium have highlighted the pervasiveness and deadliness of financial toxicity,...
Fragment Analysis as a MET Exon 14 Screening Strategy in NSCLC Tumors
Comparison of two techniques used in screening non–small cell lung cancer (NSCLC) tumor samples demonstrated that fragment analysis could detect large MET exon 14 skipping deletions that were missed by next-generation sequencing, according to findings presented at the Molecular Analysis for...
Do All Patients With Refractory Diffuse Large B-Cell Lymphoma Need CAR T-Cell Therapy?
Chimeric antigen receptor (CAR) T-cell therapy has made great strides in treating patients with relapsed or refractory diffuse large-B cell lymphoma (DLBCL) and refractory mantle cell lymphoma (MCL), but there may be newer strategies that can produce equivalent outcomes, and not all patients with...
Results From ASCO’s 2020 National Cancer Opinions Survey
As in past years, the results from ASCO’s 2020 National Cancer Opinions Survey showed a startling dichotomy in the perceptions of Americans on a variety of health-care issues. As expected, the two major events this year, the COVID-19 pandemic and a national reckoning over racial injustice,...
Lung Cancer: Precision Therapies at the Forefront
What a difference 20 years have made! In the year 2000, the results of the ECOG 1594 trial were reported at the plenary session of the ASCO Annual Meeting. The study demonstrated comparable outcomes between four different platinum-based chemotherapy regimens for the treatment of metastatic...
Surgery Improves Survival in Older Women With Early Estrogen Receptor–Positive Breast Cancer
Older women with estrogen receptor–positive breast cancer have poorer survival than younger women, but this gap might be closed by offering surgery to women over age 70 who are fit and have resectable tumors. According to a study presented at the 12th European Breast Cancer Conference (EBCC 12),...
Expert Point of View: Tim Price, MBBS, DHthSc
The invited discussant of PRODIGE 13 was Tim Price, MBBS, DHthSc, Professor at the University of Adelaide, Australia, senior consultant medical oncologist, and Director of Medical Oncology and Clinical Cancer Research at the Queen Elizabeth Hospital. As he reminded listeners, the current ASCO...
Richard Pazdur, MD, Awarded the Simon M. Shubitz Cancer Prize and Lectureship
For more than 4 decades, the University of Chicago Cancer Research Foundation’s Simon M. Shubitz Cancer Prize and Lectureship has honored an internationally renowned individual for his or her exceptional contributions to cancer research and clinical care. The recipient of this year’s award is...
Expert Point of View: Amy Tiersten, MD and Erika Hamilton, MD
Sharing their thoughts on KEYNOTE-355 were Amy Tiersten, MD, Professor of Medicine at Icahn School of Medicine at Mount Sinai, New York, and Erika Hamilton, MD, Director of the Breast and Gynecologic Research Program at Sarah Cannon Research Institute/Tennessee Oncology, Nashville, who presented...
First-Line Pembrolizumab Delays Disease Progression in PD-L1–Expressing Metastatic Triple-Negative Breast Cancer
In the phase III KEYNOTE-355 trial, pembrolizumab combined with several chemotherapy partners yielded a statistically significant and clinically meaningful improvement in progression-free survival vs chemotherapy alone in patients with previously untreated locally advanced or metastatic...
FDA Expands Approval of Companion Diagnostic for Olaparib in Prostate Cancer
On November 9, the U.S. Food and Drug Administration (FDA) approved FoundationOne Liquid CDx to be used as a companion diagnostic for olaparib. As a companion diagnostic, FoundationOne Liquid CDx will use a blood-based biopsy to identify patients with BRCA1, BRCA2, and/or ATM alterations and...
Bispecific Anti-CD20/Anti-CD19 CAR T Cells for Patients With Relapsed B-Cell Malignancies
In a single-institution phase I dose-escalation and -expansion trial reported as a letter in Nature Medicine, Shah et al found that treatment with tandem bispecific anti-CD20/anti-CD19 4-1BB–CD3ζ lentiviral (LV20.19) chimeric antigen receptor (CAR) T cells produced high response rates in adult...
Effect of ASH Choosing Wisely Recommendations on Frequency of Surveillance Imaging in Patients With DLBCL
In a retrospective analysis reported in JCO Oncology Practice, Durani et al found that use of surveillance imaging in patients with diffuse large B-cell lymphoma (DLBCL) decreased following publication of the American Society of Hematology (ASH) Choosing Wisely recommendations to limit such imaging ...
Recently Approved and Emerging Therapies for Triple-Negative Breast Cancer
“Triple-negative breast cancer has multiple different subtypes, and there are targeted therapies that can be used based on the biomarkers that we identify for each patient,” Kari B. Wisinski, MD, noted in a review of recently approved and emerging therapies at the 2020 Lynn Sage Breast Cancer...
National Academy of Medicine Elects New Members
The National Academy of Medicine recently announced the election of 90 regular members and 10 international members during its annual meeting. Election to the Academy is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated...
Selpercatinib Shows Activity in RET Fusion–Positive NSCLC and RET-Altered Thyroid Cancer
As reported inThe New England Journal of Medicine by Alexander Drilon, MD, of Memorial Sloan Kettering Cancer Center, New York, and colleagues and by Lori J. Wirth, MD, of Massachusetts General Hospital, and colleagues, the phase I/II LIBRETTO-001 trial has shown marked activity of the RET kinase ...
FDA Approves Companion Diagnostic for Three Targeted Therapies for Advanced Ovarian, Breast, and Non–Small Cell Lung Cancers
On October 27, 2020, the U.S. Food and Drug Administration (FDA) approved the FoundationOne Liquid CDx test for three new companion diagnostic indications to help match patients who may benefit from treatment with specific FDA-approved targeted therapies. The new indications are for alpelisib...
Cancer on the Global Stage: Incidence and Cancer-Related Mortality in Chile
Chile has a population of approximately 19 million living predominantly in urban areas (87.7%), with a population density of 66 inhabitants per square mile.1 For the year 2020, approximately 12% of its population was older than 65 years.1 Socioeconomic Trends and Cancer The country has experienced ...
Avelumab Maintenance Therapy Improves Overall Survival in Advanced or Metastatic Urothelial Carcinoma
As reported in The New England Journal of Medicine by Thomas Powles, MD, Barts Cancer Institute, Queen Mary University of London, and colleagues, the phase III JAVELIN Bladder 100 trial found that maintenance treatment with avelumab plus best supportive care significantly improved overall survival...
INOVATYON: Platinum-Based Regimens Remain Standard of Care in Recurrent Platinum-Sensitive Ovarian Cancer
Yet another blow has been dealt for the alkylating agent trabectedin in advanced ovarian cancer. The international phase III INOVATYON study found no improvement in overall or progression-free survival for trabectedin plus pegylated liposomal doxorubicin (PEG-LD) vs carboplatin/PEG-LD in patients...
Expert Point of View: Monika K. Krzyzanowska, MD
Formal discussant of the abstract, Monika K. Krzyzanowska, MD, a medical oncologist at Princess Margaret Cancer Centre and Professor of Medicine at the University of Toronto, said this study extends the evidence base on geriatric assessment in oncology and shows that geriatric assessment should be...
Reducing Symptomatic Toxicity Burden in Older Patients With Advanced Cancer Via Geriatric Assessment
As the number of older patients with cancer continues to rise, interventions that reduce the high rates of symptoms, toxicity, and distress in this population are urgently needed. Research presented during the 2020 ASCO Quality Care Symposium has added to the growing body of evidence supporting...
Effect of a Pay-for-Performance Program on Prescriptions and Spending for Oncology Drugs
In a study reported in the Journal of Clinical Oncology, Justin E. Bekelman, MD, and colleagues found that institution of a national insurer’s pay-for-performance program resulted in a higher rate of prescriptions for evidence-based oncology drug regimens but did not reduce overall health-care...
Study Identifies Genetic Variants Linked to Bevacizumab-Induced Adverse Events
Researchers have found two common genetic variants that may be used to predict whether patients with cancer may have severe adverse events when treated with the anti-VEGF monoclonal antibody bevacizumab. A genome-wide association study—according to researchers, the largest such study in patients...
Predicting Mortality Outcomes After Intensive Chemotherapy for AML
In a single-institution study reported in the Journal of Clinical Oncology, Palmieri et al found that the Ferrara criteria for determining fitness for intensive chemotherapy—a set of consensus criteria proposed by a panel of experts from the Italian Society of Hematology, Italian Society of...
An Integrated Framework for Improving Outcomes in Pancreatic Cancer
Drawing on several lines of ongoing research, David A. Tuveson, MD, PhD, has created a theoretical framework to consider while developing clinical trials in pancreatic cancer. In his keynote lecture at the 2020 American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer, ...
Expert Point of View: Richard Cathomas, MD
In his discussion of KEYNOTE-361 and the DANUBE trial, Richard Cathomas, MD, of Kantonsspital, Graubünden, Switzerland, said both studies yielded disappointing results. Overall, in these trials as well as current evidence from other trials, treatment of platinum-eligible (cisplatin or carboplatin)...
Checkpoint Inhibitor and Chemotherapy Combinations Fail to Move Bar as First-Line Therapy for Advanced Urothelial Cancer
Two different phase III studies found that combining an anti–PD-1/PD-L1 checkpoint inhibitor (pembrolizumab in KEYNOTE-361) with platinum-based chemotherapy or with another checkpoint inhibitor (the anti–CTLA-4 antibody tremelimumab in DANUBE) failed to significantly improve overall or...
Study Finds Universal Genetic Testing Uncovers More Inherited Mutations vs Guideline-Based Genetic Testing
Universal genetic testing may uncover inherited genetic mutations, and could individualize cancer therapies, improve survival, and strengthen the use of precision medicine. In a new study published by N. Jewel Samadder, MD, and colleagues in JAMA Oncology, researchers conducted genetic testing in...
Outcomes With Second-Line Therapy After Relapse in Patients With Early-Stage, Favorable, Classical Hodgkin Lymphoma
In an analysis of two German Hodgkin Study Group trials reported in the Journal of Clinical Oncology, Bröckelmann et al found that second-line treatment with conventional polychemotherapy resulted in similar second progression–free survival (progression-free survival-2) durations vs high-dose...
Is a High-Dose Intermittent Sunitinib Regimen for Advanced Solid Tumors Linked to Improved Survival?
A strategy for giving intermittent, high doses of the tyrosine kinase inhibitor sunitinib seemed to be well tolerated by patients with advanced cancer and increased drug concentrations in solid tumors, which was associated with improved survival. This research was presented by Gerritse et al at the ...
Study Finds Distinct Genomic Alterations May Contribute to More Aggressive Prostate Cancer in Black Men
A study by Liu et al published in Molecular Cancer Research investigated why Black men appear to be more likely to develop aggressive prostate cancer than White men. Researchers found that prostate tumors in Black men had higher frequencies of distinct genetic alterations, which may contribute to...
Are Neighborhood Poverty, Public Insurance Linked to Poorer Outcomes in Children With Cancer Undergoing Stem Cell Transplant?
Despite the increasing use of hematopoietic stem cell transplant as curative therapy for children with cancer and other life-threatening diseases, new research suggests that children who undergo a transplant for cancer may be more likely to die of treatment-related complications if they live in...
First-in-Human Study of LSD1 Inhibitor Iadademstat for Patients With Relapsed or Refractory AML
In a first-in-human phase I trial reported in the Journal of Clinical Oncology, Salamero et al identified toxicities and activity associated with iadademstat, an oral first-in-class lysine-specific histone demethylase 1A (LSD1) inhibitor, in patients with relapsed or refractory acute myeloid...
Novel Treatments Show Activity in Advanced Cervical Cancer
The treatment of recurrent or metastatic cervical cancer has not changed much in recent years, but according to preliminary trials presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2020, checkpoint inhibitors and antibody-drug conjugates may become new options. In the...
Should Patients With a Complete Response to Neoadjuvant Chemoradiation for Rectal Cancer Also Undergo Surgery?
A nonsurgical treatment option for rectal cancer that preserves quality of life may be safe for selected patients, according to a new study comparing it with standard surgical treatment. These findings were published by Beard et al in the Journal of the American College of Surgeons and were...
Development of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer
As reported in JAMA Oncology, Dess et al have developed a novel clinical prognostic stage group system for nonmetastatic prostate cancer that “meets criteria set forth by the American Joint Committee on Cancer [AJCC] Precision Medicine Core committee… [and outperforms] the existing [AJCC] system...
Jing Li, MD, PhD, on Brain Metastases: Stereotactic Radiosurgery vs Whole-Brain Radiation Therapy
Jing Li, MD, PhD, of The University of Texas MD Anderson Cancer Center, discusses phase III results showing the use of stereotactic radiosurgery in patients with 4 to 15 brain metastases, compared with whole-brain radiotherapy, may better preserve cognitive function and minimize the interruption of ...
Effect of Angiotensin II Inhibition on Response to Immunotherapy
Researchers have found that a class of commonly used heart drugs may also improve patients’ responses to PD-L1 inhibitors, according to preliminary findings presented by Strauss et al at the 32th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (Abstract 7). Angiotensin...
Gemcitabine and Daily Radiation for Patients With Muscle-Invasive Bladder Cancer
Bladder preservation with trimodality therapy may be a safe and effective alternative to cystectomy for selected patients with muscle-invasive bladder cancer, according to results from a phase II trial presented by Coen et al at the virtual 2020 American Society for Radiation Oncology (ASTRO)...
First-Line Dasatinib Plus Blinatumomab for Adult Patients With Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
In an Italian phase II trial (GIMEMA LAL2116) reported in The New England Journal of Medicine, Foà et al found that first-line induction and consolidation treatment with dasatinib plus blinatumomab produced a high rate of molecular response in adults with Philadelphia chromosome–positive acute...
Effect of Early Trastuzumab Interruption on Recurrence-Free Survival in HER2-Positive Breast Cancer
In a single-center analysis reported in a research letter in JAMA Oncology, Copeland-Halperin et al found that early trastuzumab interruption and interruption resulting in a cumulative trastuzumab dose ≤ 56 mg/kg were associated with significantly poorer recurrence-free survival in patients with...
